Search
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigationalEtrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub … [L48501] The European Commission also approved the marketing of etrasimod on February 19, 2024.[L50998]
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingGDC-0425
go.drugbank.com/drugs/DB14791InvestigationalGDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory
Categories: Heterocyclic Compounds, 1-RingPiflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationalPiflufolastat F18, also called [F-18]-DCFPyL, is a urea-based radiopharmaceutical that binds to PSMA and allows for the visualization of cancerous prostate tissue. … Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in many tissues that plays a role in folate uptake and neurotransmitter release - it is expressed in the prostate at
Synonyms: DCFPyL F-18, [F-18] DCFPyLCategories: Heterocyclic Compounds, 1-RingObefazimod
go.drugbank.com/drugs/DB14828InvestigationalABX-464 is under investigation in clinical trial NCT03905109 (Safety Evaluation of ABX464 in Patients With Moderate to Severe Active Crohn's Disease).
Categories: Heterocyclic Compounds, 2-RingUproleselan
go.drugbank.com/drugs/DB14829InvestigationalUproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy
Categories: E-Selectin, antagonists & inhibitorsEnsartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[L53263] Although there was no statistically significant difference in overall survival when compared to [crizotinib], ensartinib demonstrated a statistically significant progression-free survival improvement … [A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC).
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationaleradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. … Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.
Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household settingRitlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigational[A260122,A260127] Ritlecitinib binds covalently to Cys-909 of JAK3, a site where other JAK isoforms have a serine residue. … Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family.
Synonyms: 2-propen-1-one, 1-((2S,5R)-2-methyl-5-(7H-pyrrolo(2,3-D)pyrimidin-4-ylamino)-1-piperidinyl)-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsPyrotinib
go.drugbank.com/drugs/DB14993InvestigationalPyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
Categories: Heterocyclic Compounds, 2-RingMipicoledine
go.drugbank.com/drugs/DB15075InvestigationalMipicoledine is under investigation in clinical trial NCT01048008 (Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer).
Synonyms: (3.BETA.)-CHOLEST-5-EN-3-YL 3,5-DICHLORO-2-METHOXY-6-(TRICHLOROMETHYL)PYRIDIN-4-YL CARBONATE, CHOLEST-5-EN-3-OL (3.BETA.)-, 3-(3,5-DICHLORO-2-METHOXY-6-(TRICHLOROMETHYL)-4-PYRIDINYL CARBONATE)Categories: P-glycoprotein substrates